Alpha 2.0
Login Register
» Articles » PMID: 2720893

Treatment of Advanced Malignant Melanoma with Coumarin and Cimetidine: a Pilot Study

Overview
Journal Cancer Chemother Pharmacol
Specialty Oncology
Date 1989 Jan 1
PMID 2720893
Citations 7
Authors
M E MARSHALL
K Butler
J Cantrell
C Wiseman
L Mendelsohn
Affiliations
Soon will be listed here.
Abstract

Based on previous results demonstrating that coumarin and cimetidine render objective tumor regressions in renal cell carcinoma, we conducted a pilot study to determine whether these drugs possess activity against malignant melanoma. A total of 22 patients with advanced melanoma received 100 mg coumarin p.o. daily for 14 days; on day 15, cimetidine was added at an oral dose of 300 mg four times daily. Both drugs were continued until progression of disease. In all, 12 patients had previously been treated, but all patients had a favorable performance status. No response was observed in 19 patients. Two patients with a low tumor burden achieved a partial response and a third showed a minor response. There was no toxicity from this regimen. Although coumarin and cimetidine at this dose and schedule did not display significant activity in this study population, further studies are warranted to explore higher doses and focus on patients with relatively low tumor burdens.

Citing Articles

Coumarin-Induced Hepatotoxicity: A Narrative Review.

Pitaro M, Croce N, Gallo V, Arienzo A, Salvatore G, Antonini G Molecules. 2022; 27(24).

PMID: 36558195 PMC: 9783661. DOI: 10.3390/molecules27249063.

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

Kahale L, Hakoum M, Tsolakian I, Matar C, Barba M, Yosuico V Cochrane Database Syst Rev. 2017; 12:CD006466.

PMID: 29285754 PMC: 6389337. DOI: 10.1002/14651858.CD006466.pub6.

The anti-neoplastic effects of coumarin: an emerging concept.

Kapoor S Cytotechnology. 2013; 65(5):787-8.

PMID: 23340967 PMC: 3967608. DOI: 10.1007/s10616-013-9538-6.

Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether.

Sridar C, Kent U, Noon K, McCall A, Alworth B, Foroozesh M Drug Metab Dispos. 2008; 36(11):2234-43.

PMID: 18653744 PMC: 2736802. DOI: 10.1124/dmd.108.021493.

An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin.

MARSHALL M, Mohler J, Edmonds K, Williams B, Butler K, Ryles M J Cancer Res Clin Oncol. 1994; 120 Suppl:S39-42.

PMID: 8132703 DOI: 10.1007/BF01377124.

References
1.
MARSHALL M, Conley D, Hollingsworth P, Brown S, Thompson J . Effects of coumarin (1,2-benzopyrone) on lymphocyte, natural killer cell, and monocyte functions in vitro. J Biol Response Mod. 1989; 8(1):70-85. View
2.
Tseng Jr A, Lee W, Jakobovits E, Kirsten E, Hakam A, McLick J . Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly(ADP ribose) polymerase. Proc Natl Acad Sci U S A. 1987; 84(4):1107-11. PMC: 304371. DOI: 10.1073/pnas.84.4.1107. View
3.
Thornes R, Lynch G, SHEEHAN M . Cimetidine and coumarin therapy of melanoma. Lancet. 1982; 2(8293):328. DOI: 10.1016/s0140-6736(82)90295-1. View
4.
Pedersen L, Rose C, Langvad E . Combined treatment of advanced malignant melanoma with coumarin and cimetidine. A phase II study. Cancer Immunol Immunother. 1987; 24(2):178-9. PMC: 11038334. DOI: 10.1007/BF00205597. View
5.
LUCE J . Chemotherapy of malignant melanoma. Cancer. 1972; 30(6):1604-15. DOI: 10.1002/1097-0142(197212)30:6<1604::aid-cncr2820300629>3.0.co;2-5. View